BRPI0108394B8 - inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos - Google Patents
inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmosInfo
- Publication number
- BRPI0108394B8 BRPI0108394B8 BRPI0108394A BRPI0108394B8 BR PI0108394 B8 BRPI0108394 B8 BR PI0108394B8 BR PI0108394 A BRPI0108394 A BR PI0108394A BR PI0108394 B8 BRPI0108394 B8 BR PI0108394B8
- Authority
- BR
- Brazil
- Prior art keywords
- protein kinase
- substituted pyrrole
- kinase inhibitors
- salts
- pharmaceutical compositions
- Prior art date
Links
- YQKHNBZFHHFWHM-UHFFFAOYSA-N 1,3-dihydroindol-2-one;1h-pyrrole Chemical class C=1C=CNC=1.C1=CC=C2NC(=O)CC2=C1 YQKHNBZFHHFWHM-UHFFFAOYSA-N 0.000 title abstract 3
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title abstract 2
- 239000003909 protein kinase inhibitor Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 2
- 108060006633 protein kinase Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0117360A BRPI0117360B8 (pt) | 2000-02-15 | 2001-02-15 | inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18271000P | 2000-02-15 | 2000-02-15 | |
US21642200P | 2000-07-06 | 2000-07-06 | |
US24353200P | 2000-10-27 | 2000-10-27 | |
PCT/US2001/004813 WO2001060814A2 (en) | 2000-02-15 | 2001-02-15 | Pyrrole substituted 2-indolinone protein kinase inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
BR0108394A BR0108394A (pt) | 2004-06-22 |
BRPI0108394B1 BRPI0108394B1 (pt) | 2018-12-11 |
BRPI0108394B8 true BRPI0108394B8 (pt) | 2021-05-25 |
Family
ID=27391578
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0117360A BRPI0117360B8 (pt) | 2000-02-15 | 2001-02-15 | inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos |
BRPI0108394 BRPI0108394B8 (pt) | 2000-02-15 | 2001-02-15 | inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0117360A BRPI0117360B8 (pt) | 2000-02-15 | 2001-02-15 | inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos |
Country Status (43)
Families Citing this family (331)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6569868B2 (en) | 1998-04-16 | 2003-05-27 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
US20040226056A1 (en) * | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
JP4865129B2 (ja) | 1999-01-13 | 2012-02-01 | ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク | タンパク質キナーゼ阻害剤を設計するための新規の方法 |
PT1255752E (pt) * | 2000-02-15 | 2007-10-17 | Pharmacia & Upjohn Co Llc | Inibidores de proteína quinases: 2-indolinonas substituídas com pirrolo |
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
MY128450A (en) | 2000-05-24 | 2007-02-28 | Upjohn Co | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
US6706709B2 (en) | 2000-06-02 | 2004-03-16 | Sugen, Inc. | Indolinone derivatives as protein kinase/phosphatase inhibitors |
WO2002002551A1 (en) * | 2000-06-30 | 2002-01-10 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
ATE355275T1 (de) | 2000-10-20 | 2006-03-15 | Eisai R&D Man Co Ltd | Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen |
EP1349852A2 (en) | 2000-12-20 | 2003-10-08 | Sugen, Inc. | 4-(hetero)aryl substituted indolinones |
AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
EP1247809A3 (en) * | 2001-03-30 | 2003-12-17 | Pfizer Products Inc. | Triazine compounds useful as sorbitol dehydrogenase inhibitors |
PE20030062A1 (es) | 2001-05-30 | 2003-02-08 | Sugen Inc | Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas |
CA2452361A1 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating autoimmune diseases |
AU2002324684B2 (en) | 2001-08-15 | 2006-10-05 | Pharmacia And Upjohn Company Llc | Crystals including a malic acid salt of N-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3H-indole-3-ylidene) methyl]-2, 4-dimethyl-1H-pyrrole-3-carboxamide, processes for its preparation and compositions thereof |
AR038957A1 (es) * | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
WO2003022815A1 (en) * | 2001-09-10 | 2003-03-20 | Sugen, Inc. | 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors |
BR0213185A (pt) * | 2001-10-10 | 2004-09-14 | Sugen Inc | Derivados de 3-[4-(heterociclila substituìda)-pirrol-2-ilmetilideno]2-indolinona como inibidores de cinase |
CA2464214C (en) * | 2001-10-22 | 2011-02-08 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them |
US7005445B2 (en) | 2001-10-22 | 2006-02-28 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors and methods for designing them |
TWI259081B (en) * | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
US20030080191A1 (en) * | 2001-10-26 | 2003-05-01 | Allen Lubow | Method and apparatus for applying bar code information to products during production |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
US6797825B2 (en) | 2001-12-13 | 2004-09-28 | Abbott Laboratories | Protein kinase inhibitors |
US20050131733A1 (en) * | 2001-12-17 | 2005-06-16 | Allen Lubow | Sealable individual bar coded packets |
US7156308B2 (en) * | 2001-12-17 | 2007-01-02 | International Barcode Corporation | Double-sided bar code doubling as a single bar code |
MXPA04006271A (es) | 2001-12-27 | 2004-10-04 | Theravance Inc | Derivados de indolinona utiles como inhibidores de la proteina cinasa. |
KR100657110B1 (ko) * | 2002-02-15 | 2006-12-12 | 파마시아 앤드 업존 캄파니 엘엘씨 | 인돌리논 유도체의 제조방법 |
WO2003097854A2 (en) * | 2002-05-17 | 2003-11-27 | Sugen, Inc. | Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals |
ITMI20021620A1 (it) * | 2002-07-23 | 2004-01-23 | Novuspharma Spa | Composto ad ativita' antitumorale |
US20060084697A1 (en) * | 2002-08-08 | 2006-04-20 | Hallahan Dennis E | Pi3k antagonists as radiosensitizers |
AU2003259713A1 (en) * | 2002-08-09 | 2004-02-25 | Theravance, Inc. | Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same |
US20040121407A1 (en) * | 2002-09-06 | 2004-06-24 | Elixir Pharmaceuticals, Inc. | Regulation of the growth hormone/IGF-1 axis |
TW200418836A (en) * | 2002-09-10 | 2004-10-01 | Pharmacia Italia Spa | Formulations comprising an indolinone compound |
JP2006510727A (ja) * | 2002-11-15 | 2006-03-30 | エクセリクシス, インク. | キナーゼモジュレーター |
AR042042A1 (es) * | 2002-11-15 | 2005-06-08 | Sugen Inc | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular |
US7452913B2 (en) | 2003-02-24 | 2008-11-18 | Pharmacia & Upjohn Company | Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors |
US20040209937A1 (en) * | 2003-02-24 | 2004-10-21 | Sugen, Inc. | Treatment of excessive osteolysis with indolinone compounds |
DK1603570T5 (da) | 2003-02-26 | 2013-12-09 | Sugen Inc | Aminoheteroarylforbindelser som proteinkinaseinhibitorer |
US20040266843A1 (en) * | 2003-03-07 | 2004-12-30 | Sugen, Inc. | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) |
US7157577B2 (en) * | 2003-03-07 | 2007-01-02 | Sugen Inc. | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors |
EP1604665B1 (en) * | 2003-03-10 | 2011-05-11 | Eisai R&D Management Co., Ltd. | C-kit kinase inhibitor |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
DE10334582A1 (de) * | 2003-07-28 | 2005-02-24 | Basf Ag | Verfahren zur Herstellung von Maleinsäureanhydrid |
WO2005023765A1 (en) * | 2003-09-11 | 2005-03-17 | Pharmacia & Upjohn Company Llc | Method for catalyzing amidation reactions by the presence of co2 |
CA2540639C (en) * | 2003-10-02 | 2010-08-31 | Pharmacia & Upjohn Company Llc | Salts and polymorphs of a pyrrole-substituted indolinone compound |
WO2005037235A2 (en) * | 2003-10-16 | 2005-04-28 | Imclone Systems Incorporated | Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
AU2004288709B2 (en) | 2003-11-07 | 2011-01-06 | Novartis Vaccines And Diagnostics, Inc. | Methods for synthesizing quinolinone compounds |
WO2005044788A1 (ja) | 2003-11-11 | 2005-05-19 | Eisai Co., Ltd. | ウレア誘導体およびその製造方法 |
MXPA06006049A (es) * | 2003-11-26 | 2007-05-24 | Scripps Research Inst | Inhibidores de proteina quinasa avanzados a base de indolinona. |
EP1699477A2 (en) * | 2003-12-11 | 2006-09-13 | Theravance, Inc. | Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
US20050152943A1 (en) * | 2003-12-23 | 2005-07-14 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
WO2005118543A1 (ja) * | 2004-06-03 | 2005-12-15 | Ono Pharmaceutical Co., Ltd. | キナーゼ阻害薬およびその用途 |
WO2006002422A2 (en) | 2004-06-24 | 2006-01-05 | Novartis Vaccines And Diagnostics Inc. | Compounds for immunopotentiation |
SE0401790D0 (sv) * | 2004-07-07 | 2004-07-07 | Forskarpatent I Syd Ab | Tamoxifen response in pre- and postmenopausal breast cancer patients |
US20060009510A1 (en) * | 2004-07-09 | 2006-01-12 | Pharmacia & Upjohn Company Llc | Method of synthesizing indolinone compounds |
JP4242911B2 (ja) * | 2004-08-26 | 2009-03-25 | ファイザー・インク | プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物 |
AU2005283422C1 (en) | 2004-09-17 | 2017-02-02 | Eisai R & D Management Co., Ltd. | Medicinal composition |
CN100432071C (zh) * | 2004-11-05 | 2008-11-12 | 中国科学院上海药物研究所 | 取代1h-吲哚-2-酮类化合物及其制备方法和用途 |
GT200500321A (es) * | 2004-11-09 | 2006-09-04 | Compuestos y composiciones como inhibidores de proteina kinase. | |
US20090074787A1 (en) * | 2005-03-23 | 2009-03-19 | Pfizer, Inc., Pfizer Products, Inc. | Anti-CTLA4 Antibody and Indolinone Combination Therapy for Treatment of Cancer |
CA2604357C (en) | 2005-04-26 | 2012-01-17 | Pfizer Inc. | P-cadherin antibodies |
WO2006120557A1 (en) * | 2005-05-12 | 2006-11-16 | Pfizer Inc. | Anticancer combination therapy using sunitinib malate |
DK1922307T3 (da) | 2005-05-18 | 2012-04-02 | Array Biopharma Inc | Heterocykliske inhibitorer af MEK og fremgangsmåder til anvendelse heraf |
BRPI0611375A2 (pt) | 2005-05-23 | 2010-08-31 | Novartis Ag | formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona |
BRPI0611419A2 (pt) * | 2005-05-26 | 2010-09-08 | Scripps Research Inst | composto, sal, tautÈmero ou pró-fármaco, método para a modulação da atividade catalìtica de uma proteìna cinase e processo para a sìntese de uma pirrolil-indolinona |
EP1925941B1 (en) | 2005-08-01 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
EA201300320A1 (ru) | 2005-09-07 | 2014-02-28 | Эмджен Фримонт Инк. | Моноклональные антитела человека к киназе-1, подобной рецептору активина |
MX2008002415A (es) * | 2005-09-19 | 2008-03-27 | Pfizer Prod Inc | Formas salinas solidas de una 2-indolinona sustituida con pirrol. |
CA2627598C (en) | 2005-11-07 | 2013-06-25 | Eisai R & D Management Co., Ltd. | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
UA96139C2 (uk) | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
KR20080083341A (ko) * | 2005-12-29 | 2008-09-17 | 더 스크립스 리서치 인스티튜트 | 인돌리논의 아미노산 유도체 기재의 단백질 키나제 억제제 |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
CN101007801A (zh) * | 2006-01-27 | 2007-08-01 | 上海恒瑞医药有限公司 | 吡咯取代的2-二氢吲哚酮衍生物、其制法与医药上的用途 |
AR060358A1 (es) | 2006-04-06 | 2008-06-11 | Novartis Vaccines & Diagnostic | Quinazolinas para la inhibicion de pdk 1 |
TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
US20070293491A1 (en) | 2006-04-19 | 2007-12-20 | Novartis Vaccines And Diagnostics, Inc. | Indazole compounds and methods for inhibition of cdc7 |
UA91129C2 (ru) | 2006-05-09 | 2010-06-25 | Пфайзер Продактс Инк. | Производные циклоалкиламинокислот и фармацевтическая композиция, которая их содержит |
CN101443009A (zh) | 2006-05-18 | 2009-05-27 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
DE102006024834B4 (de) * | 2006-05-24 | 2010-07-01 | Schebo Biotech Ag | Neue Indol-Pyrrol-Derivate und deren Verwendungen |
JPWO2008001956A1 (ja) * | 2006-06-29 | 2009-12-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 肝線維症治療剤 |
US7838542B2 (en) | 2006-06-29 | 2010-11-23 | Kinex Pharmaceuticals, Llc | Bicyclic compositions and methods for modulating a kinase cascade |
US20080025946A1 (en) | 2006-07-13 | 2008-01-31 | Sivakumar Pallavur V | Interleukin 21 and tyrosine kinase inhibitor combination therapy |
CL2007002225A1 (es) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
TW200817409A (en) | 2006-08-04 | 2008-04-16 | Takeda Pharmaceutical | Fused heterocyclic derivative and use thereof |
MX2009001946A (es) * | 2006-08-23 | 2009-03-05 | Kudos Pharm Ltd | Derivados de 2-metilmorfolin-pirido-, pirazo- y pirimido- pirimidina como inhibidores de mtor. |
EP2065372B1 (en) | 2006-08-28 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
ES2565683T3 (es) | 2006-09-15 | 2016-04-06 | Xcovery, Inc. | Compuestos inhibidores de quinasa |
MX2009004700A (es) | 2006-11-06 | 2009-05-15 | Supergen Inc | Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa. |
CN101535302A (zh) | 2006-11-06 | 2009-09-16 | 株式会社泰丽巴镠斯 | 新型羟基吲哚衍生物 |
EP2123649B1 (en) | 2006-12-04 | 2012-02-29 | Jiangsu Simcere Pharmaceutical R&D Co., Ltd. | 3-pyrrolo-cyclohexylene-2-dihydro-indolinone derivatives and uses thereof |
WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
JP4523073B2 (ja) | 2007-02-06 | 2010-08-11 | ファイザー・インク | 癌を治療するためのHSP−90阻害剤としての2−アミノ−5,7−ジヒドロ−6H−ピロロ[3,4−d]ピリミジン誘導体 |
EP2138497A4 (en) | 2007-03-20 | 2012-01-04 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
US20090042906A1 (en) * | 2007-04-26 | 2009-02-12 | Massachusetts Institute Of Technology | Methods for treating cancers associated with constitutive egfr signaling |
WO2008138184A1 (fr) | 2007-05-14 | 2008-11-20 | Shanghai Hengrui Pharmaceutical Co.Ltd. | Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases |
WO2008145398A1 (en) * | 2007-06-01 | 2008-12-04 | Pfizer Italia S.R.L. | 4-arylpyrrole substituted 2-indoline derivatives active as protein kinase inhibitors |
US8304557B2 (en) | 2007-06-05 | 2012-11-06 | Takeda Pharmaceutical Company Limited | Fused heterocycle derivatives and use thereof |
JP5270553B2 (ja) | 2007-08-23 | 2013-08-21 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
US20090062368A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched sunitinib |
EP3037419B1 (en) | 2007-09-06 | 2019-09-04 | Boston Biomedical, Inc. | Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases |
NZ585261A (en) | 2007-10-11 | 2011-10-28 | Astrazeneca Ab | Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors |
CA2704000C (en) | 2007-11-09 | 2016-12-13 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
US20100256392A1 (en) * | 2007-11-21 | 2010-10-07 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
EP2220072A2 (en) * | 2007-11-21 | 2010-08-25 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
EP2229380A1 (en) * | 2007-12-12 | 2010-09-22 | Medichem, S.A. | Polymorphic forms of a 3-pyrrole substituted 2-indolinone |
CA2706571C (en) | 2007-12-19 | 2012-11-27 | Genentech, Inc. | 5-anilinoimidazopyridines and methods of use |
CN101952282A (zh) | 2007-12-20 | 2011-01-19 | 诺瓦提斯公司 | 用作pi 3激酶抑制剂的噻唑衍生物 |
CA2708176A1 (en) | 2007-12-21 | 2009-07-02 | Genentech, Inc. | Azaindolizines and methods of use |
CA2713930A1 (en) * | 2008-01-29 | 2009-08-06 | Eisai R & D Management Co., Ltd. | Combined use of angiogenesis inhibitor and taxane |
WO2009100929A1 (en) * | 2008-02-13 | 2009-08-20 | Ratiopharm Gmbh | Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide |
EP2090306A1 (en) | 2008-02-13 | 2009-08-19 | Ratiopharm GmbH | Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
EP2113248A1 (en) | 2008-04-29 | 2009-11-04 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide |
CN101255154B (zh) * | 2008-02-18 | 2011-09-07 | 靳广毅 | 一种取代的2-吲哚啉酮衍生物和制备方法及其应用 |
EP2252607A2 (en) * | 2008-02-21 | 2010-11-24 | Generics [UK] Limited | Novel polymorphs and processes for their preparation |
EP2098521A1 (en) * | 2008-03-06 | 2009-09-09 | Ratiopharm GmbH | Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation |
CA2720164A1 (en) * | 2008-03-31 | 2009-10-08 | Teva Pharmaceutical Industries Ltd. | Processes for preparing sunitinib and salts thereof |
EP2280960A1 (en) * | 2008-04-16 | 2011-02-09 | Natco Pharma Limited | Novel polymorphic forms of sunitinib base |
US8158656B2 (en) * | 2008-05-16 | 2012-04-17 | Shenzhen Chipscreen Biosciences Ltd. | 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors |
EP2292613B1 (en) * | 2008-05-23 | 2015-09-30 | Shanghai Institute of Pharmaceutical Industry | Dihydroindolinone derivatives |
US8263547B2 (en) | 2008-05-28 | 2012-09-11 | Massachusetts Institute Of Technology | DISC-1 pathway activators in the control of neurogenesis |
EP2313371B1 (en) * | 2008-06-13 | 2012-08-15 | Medichem, S.A. | Process for preparing a 3-pyrrole substituted 2-indolinone malate salt |
KR20110036055A (ko) * | 2008-06-23 | 2011-04-06 | 낫코 파마 리미티드 | 고순도의 수니티닙 및 이의 약학적으로 허용가능한 염의 개선된 제조 방법 |
EP2138167A1 (en) | 2008-06-24 | 2009-12-30 | ratiopharm GmbH | Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
WO2009156837A2 (en) * | 2008-06-26 | 2009-12-30 | Medichem, S.A. | Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt |
AU2009267048A1 (en) * | 2008-06-30 | 2010-01-07 | Cylene Pharmaceuticals, Inc. | Oxindole compounds |
CA2729303A1 (en) | 2008-06-30 | 2010-01-14 | Angioblast Systems, Inc. | Treatment of eye diseases and excessive neovascularization using a combined therapy |
DE102008031038A1 (de) | 2008-06-30 | 2009-12-31 | Alexander Priv.-Doz. Dr. Dömling | Sutent zur Anwendung in der Organtransplantation |
JP2011526615A (ja) * | 2008-07-02 | 2011-10-13 | ジェネリクス・(ユーケー)・リミテッド | 3−ピロール置換2−インドリノン誘導体の調製 |
JP2011527330A (ja) * | 2008-07-10 | 2011-10-27 | ジェネリクス・(ユーケー)・リミテッド | スニチニブリンゴ酸塩の結晶形の調製方法 |
EP2373642A2 (en) | 2008-07-24 | 2011-10-12 | Teva Pharmaceutical Industries Ltd | Process for the preparation of sunitinib malate via sunitinib acetate and their polymorphs |
WO2010010454A2 (en) | 2008-07-24 | 2010-01-28 | Medichem, S.A. | Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt |
WO2010017541A2 (en) * | 2008-08-08 | 2010-02-11 | The Johns Hopkins University | Compositions and methods for treatment of neurodegenerative disease |
AU2009288289B2 (en) * | 2008-08-25 | 2012-11-08 | Amplimmune, Inc. | PD-1 antagonists and methods of use thereof |
CN102197034A (zh) * | 2008-08-25 | 2011-09-21 | 基因里克斯(英国)有限公司 | 舒尼替尼的新型多晶型物及其制备方法 |
JP2012500837A (ja) * | 2008-08-25 | 2012-01-12 | ジェネリクス・(ユーケー)・リミテッド | 新規な結晶型およびその調製方法 |
PE20110435A1 (es) | 2008-08-25 | 2011-07-20 | Amplimmune Inc | Composiciones antagonistas del pd-1 |
WO2010026388A1 (en) * | 2008-09-05 | 2010-03-11 | Imperial Innovations Limited | Isatin derivatives for use as in vivo imaging agents |
KR20110057244A (ko) | 2008-09-19 | 2011-05-31 | 메디뮨 엘엘씨 | Dll4에 대한 항체 및 이의 용도 |
AR073807A1 (es) * | 2008-10-10 | 2010-12-01 | Medichem Sa | Proceso para preparar el malato de sunitinib, sal de un acido mas debil que el malato como compuesto intermediario, y proceso para preparar dicha sal intermediaria. |
EP2181991A1 (en) | 2008-10-28 | 2010-05-05 | LEK Pharmaceuticals D.D. | Novel salts of sunitinib |
EP2186809A1 (en) * | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | New crystal form of sunitinib malate |
US20100222371A1 (en) * | 2008-11-20 | 2010-09-02 | Children's Medical Center Corporation | Prevention of surgical adhesions |
US8697874B2 (en) | 2008-12-01 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
UY32351A (es) | 2008-12-22 | 2010-07-30 | Astrazeneca Ab | Compuestos de pirimidinil indol para uso como inhibidores de atr |
WO2010072740A2 (en) | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF |
EP2373643A4 (en) | 2009-01-02 | 2013-08-07 | Hetero Research Foundation | NEW SUNITINIB MALATE POLYMORPHS |
TW202241853A (zh) | 2009-01-16 | 2022-11-01 | 美商艾克塞里克斯公司 | 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途 |
US8426402B2 (en) | 2009-02-05 | 2013-04-23 | Immunogen, Inc. | Benzodiazepine derivatives |
US20100204221A1 (en) | 2009-02-09 | 2010-08-12 | Hariprasad Vankayalapati | Pyrrolopyrimidinyl axl kinase inhibitors |
US20100222381A1 (en) | 2009-02-27 | 2010-09-02 | Hariprasad Vankayalapati | Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors |
US9265764B2 (en) * | 2009-02-27 | 2016-02-23 | Massachusetts Institute Of Technology | Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders |
WO2010103094A1 (en) | 2009-03-13 | 2010-09-16 | Cellzome Limited | PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
US20120040955A1 (en) | 2009-04-14 | 2012-02-16 | Richard John Harrison | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
US8530492B2 (en) | 2009-04-17 | 2013-09-10 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
EP2255792A1 (en) | 2009-05-20 | 2010-12-01 | Ratiopharm GmbH | Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide |
US8211901B2 (en) | 2009-05-22 | 2012-07-03 | Shenzhen Chipscreen Biosciences Ltd. | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors |
EP2264027A1 (en) * | 2009-05-27 | 2010-12-22 | Ratiopharm GmbH | Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
US8389580B2 (en) | 2009-06-02 | 2013-03-05 | Duke University | Arylcyclopropylamines and methods of use |
CN101906076B (zh) | 2009-06-04 | 2013-03-13 | 深圳微芯生物科技有限责任公司 | 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用 |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
WO2011004200A1 (en) | 2009-07-10 | 2011-01-13 | Generics [Uk] Limited | Novel pyrrole derivatives |
FR2948940B1 (fr) | 2009-08-04 | 2011-07-22 | Servier Lab | Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US20120172385A1 (en) | 2009-09-11 | 2012-07-05 | Richard John Harrison | Ortho substituted pyrimidine compounds as jak inhibitors |
AU2010296849A1 (en) | 2009-09-16 | 2012-05-03 | Ranbaxy Laboratories Limited | Salts of sunitinib |
AR078675A1 (es) | 2009-10-20 | 2011-11-23 | Cellzome Ltd | Derivados de pirazolo[3,4-d]pirimidina inhibidores de jak quinasas, composiciones farmaceuticas que los comprenden, metodo para prepararlos y uso de los mismos para el tratamiento o profilaxis de trastornos inmunologicos, inflamatorios y autoinmunes. |
US20120271056A1 (en) | 2009-11-12 | 2012-10-25 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form i of l-malic acid salt of sunitinib |
US8916716B2 (en) | 2009-11-19 | 2014-12-23 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form II of L-malic acid salt of sunitinib |
HUE037159T2 (hu) | 2009-11-24 | 2018-08-28 | Medimmune Ltd | Targetált kötõdõ ágensek B7-H1 ellen |
JP2013512859A (ja) | 2009-12-03 | 2013-04-18 | 大日本住友製薬株式会社 | トール様受容体(tlr)を介して作用するイミダゾキノリン |
WO2011095802A1 (en) | 2010-02-02 | 2011-08-11 | Generics [Uk] Limited | Hplc method for analyzing sunitinib |
WO2011100325A2 (en) * | 2010-02-09 | 2011-08-18 | Sicor Inc. | Polymorphs of sunitinib salts |
JP5841072B2 (ja) | 2010-02-10 | 2016-01-06 | イミュノジェン・インコーポレーテッド | Cd20抗体およびその使用 |
BR112012019635A2 (pt) | 2010-02-22 | 2016-05-03 | Hoffmann La Roche | compostos inibidores de pirido[3,2-d] pirimidina pi3k delta e métodos de uso |
WO2011104555A2 (en) | 2010-02-25 | 2011-09-01 | Generics [Uk] Limited | Novel process |
EP2542536B1 (en) | 2010-03-04 | 2015-01-21 | Cellzome Limited | Morpholino substituted urea derivatives as mtor inhibitors |
EP2542550A1 (en) | 2010-03-04 | 2013-01-09 | Ranbaxy Laboratories Limited | Process for the direct preparation of malic acid salt of sunitinib |
EP2545034A1 (en) * | 2010-03-10 | 2013-01-16 | Synthon B.V. | A process for amidation of pyrrole carboxylate compounds |
AU2011228765A1 (en) | 2010-03-18 | 2012-10-11 | Ranbaxy Laboratories Limited | Process for the preparation of malic acid salt of sunitinib |
US9162981B2 (en) | 2010-03-23 | 2015-10-20 | The Johns Hopkins University | Compositions and methods for treatment of neurodegenerative disease |
WO2011128699A2 (en) * | 2010-04-16 | 2011-10-20 | Generics [Uk] Limited | Novel process |
EP2566867A1 (en) | 2010-04-30 | 2013-03-13 | Cellzome Limited | Pyrazole compounds as jak inhibitors |
WO2011138565A1 (fr) | 2010-05-05 | 2011-11-10 | Biorebus | Association pharmaceutique contenant l'acide lipoïque, l'acide hydroxycitrique et une somatostatine a titre de principes actifs |
EP2392324A1 (en) | 2010-06-01 | 2011-12-07 | Societe De Coordination De Recherches Therapeutiques | Rhenium complexes and their pharmaceutical use |
SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
ES2573515T3 (es) | 2010-06-25 | 2016-06-08 | Eisai R&D Management Co., Ltd. | Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados |
US20130143915A1 (en) | 2010-07-01 | 2013-06-06 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
MX2013000083A (es) | 2010-07-09 | 2013-02-26 | Genentech Inc | Anticuerpos de anti-neuropilina y metodos de uso. |
AR082418A1 (es) | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
WO2012022681A2 (en) | 2010-08-20 | 2012-02-23 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors |
WO2012027716A1 (en) | 2010-08-27 | 2012-03-01 | Collabrx, Inc. | Method to treat melanoma in braf inhibitor-resistant subjects |
WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
JP5732541B2 (ja) | 2010-11-01 | 2015-06-10 | サイノファーム (クンシャン) バイオケミカル テクノロジ カンパニー リミテッド | 2−シリロキシ−ピロールを使用する3−((ピロール−2−イル)メチレン)−2−ピロロンの調製方法 |
WO2012059941A1 (en) * | 2010-11-04 | 2012-05-10 | Ind-Swift Laboratories Limited | Process for preparation of sunitinib malate and salts thereof |
AU2011328237A1 (en) | 2010-11-09 | 2013-05-23 | Cellzome Limited | Pyridine compounds and aza analogues thereof as TYK2 inhibitors |
WO2012068487A1 (en) | 2010-11-18 | 2012-05-24 | Synta Pharmaceuticals Corp. | Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status |
AU2011329656B2 (en) | 2010-11-19 | 2017-01-05 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
AR083868A1 (es) | 2010-12-03 | 2013-03-27 | Lilly Co Eli | Compuestos de oxazol[5,4-b]piridin-5-ilo |
US9827326B2 (en) * | 2010-12-23 | 2017-11-28 | Nektar Therapeutics | Polymer-sunitinib conjugates |
EP2654797B1 (en) | 2010-12-23 | 2017-11-08 | Nektar Therapeutics | Polymer-des-ethyl sunitinib conjugates |
TW201309700A (zh) | 2011-01-31 | 2013-03-01 | Novartis Ag | 新穎雜環衍生物 |
WO2012112708A1 (en) | 2011-02-15 | 2012-08-23 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and methods of preparation |
JP5937112B2 (ja) | 2011-02-17 | 2016-06-22 | カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドCancer Therapeutics Crc Pty Limited | 選択的fak阻害剤 |
US20130324532A1 (en) | 2011-02-17 | 2013-12-05 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
GB201103578D0 (en) | 2011-03-02 | 2011-04-13 | Sabrepharm Ltd | Dipyridinium derivatives |
US8630703B2 (en) | 2011-03-09 | 2014-01-14 | Technion Research & Development Foundation Limited | Treatment utilizing hydrophobic weak bases chemotherapeutic agents and illumination |
CN102115469A (zh) * | 2011-03-21 | 2011-07-06 | 浙江大学 | 吲哚啉-2-酮类衍生物的制备和用途 |
JP2014510122A (ja) | 2011-04-04 | 2014-04-24 | セルゾーム リミテッド | mTOR阻害剤としてのジヒドロピロロピリミジン誘導体 |
WO2012139019A2 (en) | 2011-04-08 | 2012-10-11 | Beta Pharma, Inc. | New indolinone protein kinase inhibitors |
WO2012143320A1 (en) | 2011-04-18 | 2012-10-26 | Cellzome Limited | (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors |
RU2580609C2 (ru) | 2011-04-18 | 2016-04-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое терапевтическое средство |
CN102898402B (zh) * | 2011-04-26 | 2016-01-20 | 北京大学 | 一种苯并异硒唑酮修饰的吡咯甲酸酯取代的吲哚酮类化合物及其应用 |
ES2841809T3 (es) | 2011-06-03 | 2021-07-09 | Eisai R&D Man Co Ltd | Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib |
WO2013013188A1 (en) | 2011-07-21 | 2013-01-24 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
CN103781780B (zh) | 2011-07-28 | 2015-11-25 | 赛尔佐姆有限公司 | 作为jak抑制剂的杂环基嘧啶类似物 |
WO2013017479A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
EP2739252A4 (en) | 2011-08-05 | 2015-08-12 | Forsight Vision4 Inc | SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE |
JP2014531449A (ja) | 2011-09-20 | 2014-11-27 | セルゾーム リミティッド | キナーゼ阻害剤としてのピラゾロ[4,3―c]ピリジン誘導体 |
CN103917530B (zh) | 2011-09-21 | 2016-08-24 | 塞尔佐姆有限公司 | 作为mtor抑制剂的吗啉代取代的脲或氨基甲酸衍生物 |
CN103946222B (zh) | 2011-10-07 | 2016-12-28 | 塞尔佐姆有限公司 | 作为mtor抑制剂的吗啉代取代的双环嘧啶脲或氨基甲酸衍生物 |
CN102499917B (zh) | 2011-10-25 | 2014-12-17 | 澳门大学 | 吲哚酮类化合物在制备神经保护药物中的应用 |
MX340452B (es) | 2011-10-28 | 2016-07-08 | Novartis Ag | Novedosos derivados de purina y su uso en el tratamiento de enfermedades. |
CN103130774B (zh) * | 2011-11-22 | 2016-06-22 | 齐鲁制药有限公司 | 具有酪氨酸激酶抑制作用的化合物及其制备方法和应用 |
CN103127096B (zh) * | 2011-12-02 | 2015-11-25 | 杨子娇 | 吡咯基取代的吲哚类化合物在治疗青光眼病的应用 |
JP2015500862A (ja) | 2011-12-23 | 2015-01-08 | セルゾーム リミティッド | キナーゼ阻害剤としてのピリミジン−2,4−ジアミン誘導体 |
US20130178520A1 (en) | 2011-12-23 | 2013-07-11 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
CN102491932A (zh) * | 2011-12-26 | 2012-06-13 | 天津科技大学 | 一种3-吲哚啉酮类衍生物及其制备方法及其应用 |
CN104114550A (zh) | 2012-03-23 | 2014-10-22 | 劳拉斯实验室私人有限公司 | 制备舒尼替尼及其酸加成盐的改进的方法 |
EP2838538B1 (en) | 2012-04-20 | 2017-03-15 | Annji Pharmaceutical Co., Ltd. | Cyclopropanecarboxylate esters of purine analogues |
PL399027A1 (pl) | 2012-04-27 | 2013-10-28 | Instytut Farmaceutyczny | Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu |
CN102653521B (zh) * | 2012-04-27 | 2014-08-06 | 首都师范大学 | 吲哚-2-酮的哌嗪硫代甲酰肼衍生物及其制备方法和用途 |
MX359257B (es) | 2012-05-04 | 2018-09-19 | Pfizer | Antígenos asociados a próstata y regímenes de inmunoterapia basados en vacuna. |
AU2013263043B2 (en) | 2012-05-16 | 2016-06-16 | Novartis Ag | Dosage regimen for a PI-3 kinase inhibitor |
US9738724B2 (en) | 2012-06-08 | 2017-08-22 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
EP2863955B1 (en) | 2012-06-26 | 2016-11-23 | Sutro Biopharma, Inc. | Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
EP2885291A4 (en) | 2012-08-17 | 2015-11-04 | Cancer Therapeutics Crc Pty Ltd | INHIBITORS OF VEGFR3 |
EP2887965A1 (en) | 2012-08-22 | 2015-07-01 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
SI3584255T1 (sl) | 2012-08-31 | 2022-05-31 | Sutro Biopharma, Inc | Modificirane aminokisline, ki vsebujejo azido skupino |
WO2014041349A1 (en) | 2012-09-12 | 2014-03-20 | Cancer Therapeutics Crc Pty Ltd | Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors |
WO2014045101A1 (en) | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
JP6243918B2 (ja) | 2012-10-16 | 2017-12-06 | トレロ ファーマシューティカルズ, インコーポレイテッド | Pkm2調節因子およびそれらの使用方法 |
US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
AU2013364953A1 (en) | 2012-12-21 | 2015-04-30 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
WO2014134483A2 (en) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
EP2961435B1 (en) | 2013-02-28 | 2019-05-01 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
JP6378308B2 (ja) * | 2013-03-13 | 2018-08-22 | ボストン バイオメディカル, インコーポレイテッド | がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての3−(アリールまたはヘテロアリール)メチレンインドリン−2−オン誘導体 |
CA2905496A1 (en) | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
WO2014151871A2 (en) | 2013-03-14 | 2014-09-25 | Tolero Pharmaceuticals, Inc. | Jak2 and alk2 inhibitors and methods for their use |
AR095443A1 (es) | 2013-03-15 | 2015-10-14 | Fundación Centro Nac De Investig Oncológicas Carlos Iii | Heterociclos condensados con acción sobre atr |
US9206188B2 (en) | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
CN104119321B (zh) * | 2013-04-28 | 2017-09-08 | 齐鲁制药有限公司 | 二氢吲哚酮衍生物的二马来酸盐及其多晶型物 |
US10517861B2 (en) | 2013-05-14 | 2019-12-31 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
ES2658039T3 (es) | 2013-07-10 | 2018-03-08 | Sutro Biopharma, Inc. | Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso |
FR3008411B1 (fr) * | 2013-07-12 | 2015-07-03 | Servier Lab | Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent |
WO2015031604A1 (en) | 2013-08-28 | 2015-03-05 | Crown Bioscience, Inc. | Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same |
WO2015054658A1 (en) | 2013-10-11 | 2015-04-16 | Sutro Biopharma, Inc. | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use |
CA2838585A1 (en) | 2013-10-18 | 2015-04-18 | Hari Babu Matta | An ascorbic acid salt of sunitinib |
US9604968B2 (en) | 2013-10-18 | 2017-03-28 | Sun Pharmaceutical Industries Limited | Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation |
SG10201910889VA (en) | 2013-11-01 | 2020-01-30 | Pfizer | Vectors for expression of prostate-associated antigens |
TN2016000179A1 (en) | 2013-12-06 | 2017-10-06 | Novartis Ag | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. |
CN104829596B (zh) | 2014-02-10 | 2017-02-01 | 石家庄以岭药业股份有限公司 | 吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途 |
CN103923014A (zh) * | 2014-05-05 | 2014-07-16 | 宁夏宝马药业有限公司 | 环肌酸制备方法 |
MY182793A (en) | 2014-08-08 | 2021-02-05 | Forsight Vision4 Inc | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
HRP20221047T1 (hr) | 2014-08-28 | 2022-11-11 | Eisai R&D Management Co., Ltd. | Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
SG11201705767PA (en) | 2015-01-13 | 2017-08-30 | Univ Kyoto | Agent for preventing and/or treating amyotrophic lateral sclerosis |
FI3263106T3 (fi) | 2015-02-25 | 2024-01-03 | Eisai R&D Man Co Ltd | Menetelmä kinoliinijohdannaisen kitkeryyden tukahduttamiseksi |
CA2978226A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharpe & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
JP6851978B2 (ja) | 2015-04-20 | 2021-03-31 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | ミトコンドリアプロファイリングによるアルボシジブ応答の予測 |
WO2016184793A1 (en) | 2015-05-15 | 2016-11-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma |
TR201911032T4 (tr) | 2015-05-18 | 2019-08-21 | Tolero Pharmaceuticals Inc | Artırılmış biyoyararlanıma sahip alvocıdıb ön ilaçları. |
GB201510019D0 (en) | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
CA2988707C (en) | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
RU2759963C2 (ru) | 2015-08-03 | 2021-11-19 | Сумитомо Даиниппон Фарма Онколоджи, Инк. | Комбинированные терапии для лечения рака |
CA2999766A1 (en) | 2015-09-22 | 2017-03-30 | Graybug Vision, Inc. | Compounds and compositions for the treatment of ocular disorders |
GB2543550A (en) | 2015-10-21 | 2017-04-26 | Hox Therapeutics Ltd | Peptides |
MX2018005298A (es) | 2015-11-02 | 2018-06-22 | Novartis Ag | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. |
JP2018533596A (ja) | 2015-11-12 | 2018-11-15 | グレイバグ ビジョン インコーポレイテッド | 医学療法のための凝集マイクロ粒子 |
CA3011455A1 (en) | 2016-01-27 | 2017-08-03 | Sutro Biopharma, Inc. | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates |
WO2017139417A1 (en) | 2016-02-08 | 2017-08-17 | Vitrisa Therapeutics, Inc. | Compositions with improved intravitreal half-life and uses thereof |
EP3228630A1 (en) | 2016-04-07 | 2017-10-11 | IMBA-Institut für Molekulare Biotechnologie GmbH | Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer |
CN107459519A (zh) | 2016-06-06 | 2017-12-12 | 上海艾力斯医药科技有限公司 | 稠合嘧啶哌啶环衍生物及其制备方法和应用 |
AU2017321973A1 (en) | 2016-09-02 | 2019-03-07 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating B cell disorders |
WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
CA3041840A1 (en) | 2016-10-28 | 2018-05-03 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating ezh2-mediated cancer |
WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
US10786502B2 (en) | 2016-12-05 | 2020-09-29 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
ES2906439T3 (es) | 2016-12-05 | 2022-04-18 | Apros Therapeutics Inc | Compuestos de pirimidina que contienen grupos ácidos |
US11541051B2 (en) | 2016-12-08 | 2023-01-03 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
EP3362471B1 (en) | 2016-12-19 | 2021-11-17 | Sumitomo Dainippon Pharma Oncology, Inc. | Profiling peptides and methods for sensitivity profiling |
CN106916143B (zh) * | 2017-03-14 | 2019-09-27 | 哈尔滨医科大学 | 一种预防和治疗冠心病的药物及其应用 |
WO2018175922A1 (en) | 2017-03-23 | 2018-09-27 | Graybug Vision, Inc. | Drugs and compositions for the treatment of ocular disorders |
JP2020519585A (ja) | 2017-05-10 | 2020-07-02 | グレイバグ ビジョン インコーポレイテッド | 医学療法のための延長放出マイクロ粒子及びその懸濁液 |
EP3658588A1 (en) | 2017-07-26 | 2020-06-03 | Sutro Biopharma, Inc. | Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma |
US11497756B2 (en) | 2017-09-12 | 2022-11-15 | Sumitomo Pharma Oncology, Inc. | Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib |
KR20200051802A (ko) | 2017-09-18 | 2020-05-13 | 서트로 바이오파마, 인크. | 항-엽산 수용체 알파 항체 접합체 및 이의 용도 |
WO2019075367A1 (en) | 2017-10-13 | 2019-04-18 | Tolero Pharmaceuticals, Inc. | PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER |
NL2019801B1 (en) | 2017-10-25 | 2019-05-02 | Univ Leiden | Delivery vectors |
CN112154146A (zh) | 2018-03-06 | 2020-12-29 | 西奈山伊坎医学院 | 丝氨酸苏氨酸激酶(akt)降解/破坏化合物和使用方法 |
EP3539536A1 (en) | 2018-03-15 | 2019-09-18 | MH10 Spolka z ograniczona odpowiedzialnoscia | A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i |
WO2019236496A1 (en) | 2018-06-04 | 2019-12-12 | Apros Therapeutics, Inc. | Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7 |
GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
JP2021530554A (ja) | 2018-07-26 | 2021-11-11 | スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド | 異常なacvr1発現を伴う疾患を処置するための方法およびそこで使用するためのacvr1阻害剤 |
WO2020060944A1 (en) | 2018-09-17 | 2020-03-26 | Sutro Biopharma, Inc. | Combination therapies with anti-folate receptor antibody conjugates |
US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
CA3124330A1 (en) | 2018-12-21 | 2020-06-25 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
AU2020221247A1 (en) | 2019-02-12 | 2021-08-05 | Sumitomo Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
WO2020188015A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
EP3941463A1 (en) | 2019-03-22 | 2022-01-26 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
EP3958845A1 (en) | 2019-04-25 | 2022-03-02 | Synthon B.V. | Pharmaceutical composition comprising amorphous sunitinib |
EP3962951A1 (en) | 2019-05-03 | 2022-03-09 | Sutro Biopharma, Inc. | Anti-bcma antibody conjugates |
WO2020227325A1 (en) | 2019-05-06 | 2020-11-12 | Icahn School Of Medicine At Mount Sinai | Heterobifunctional compounds as degraders of hpk1 |
AU2020335054A1 (en) | 2019-08-31 | 2022-03-24 | Etern Biopharma (Shanghai) Co., Ltd. | Pyrazole derivative for FGFR inhibitor and preparation method therefor |
AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
EP4114852A1 (en) | 2020-03-03 | 2023-01-11 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
CN111233841A (zh) * | 2020-03-17 | 2020-06-05 | 湖北扬信医药科技有限公司 | 一种舒尼替尼有关物质及其制备方法和用途 |
WO2023278424A1 (en) * | 2021-06-28 | 2023-01-05 | The Regents Of The University Of California | Methods for treating and ameliorating t cell related diseases |
CN113717159A (zh) * | 2021-09-16 | 2021-11-30 | 中国药科大学 | 吲哚酮类化合物及其药物组合物、制备方法及用途 |
WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
WO2023228095A1 (en) | 2022-05-24 | 2023-11-30 | Daiichi Sankyo Company, Limited | Dosage regimen of an anti-cdh6 antibody-drug conjugate |
US20240058465A1 (en) | 2022-06-30 | 2024-02-22 | Sutro Biopharma, Inc. | Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates |
WO2024017372A1 (zh) * | 2022-07-22 | 2024-01-25 | 成都百裕制药股份有限公司 | 一种吲哚酮衍生物及其应用 |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL230368A (US06573293-20030603-C00084.png) | 1957-08-19 | |||
DE878539C (de) | 1939-08-17 | 1953-06-05 | Hoechst Ag | Verfahren zur Herstellung von Methinfarbstoffen |
BE507136A (US06573293-20030603-C00084.png) | 1950-11-18 | |||
BE553661A (US06573293-20030603-C00084.png) | 1955-12-23 | |||
BE558210A (US06573293-20030603-C00084.png) | 1956-06-08 | |||
NL251055A (US06573293-20030603-C00084.png) | 1959-04-29 | |||
FR1398224A (fr) | 1964-05-06 | 1965-05-07 | Ici Ltd | Procédé de teinture de matières textiles de polyacrylonitrile |
US3308134A (en) | 1965-10-22 | 1967-03-07 | Mcneilab Inc | Spiro(indan-2, 3'-indoline)-1, 2'-diones |
US3551571A (en) | 1967-05-19 | 1970-12-29 | Endo Lab | Methods for reducing pain,reducing fever and alleviating inflammatory syndromes with heteroaromatic pyrrol-3-yl ketones |
US3564016A (en) | 1968-03-07 | 1971-02-16 | Endo Lab | Method of decarbonylation |
US4070366A (en) | 1968-06-12 | 1978-01-24 | Canadian Patents & Development Limited | Alkylation process |
FR1599772A (US06573293-20030603-C00084.png) | 1968-09-17 | 1970-07-20 | ||
US3922163A (en) | 1970-01-30 | 1975-11-25 | Upjohn Co | Organic compounds and process |
US3715364A (en) | 1970-12-28 | 1973-02-06 | Merck & Co Inc | Nitroimidazole carboxamides |
DE2159362A1 (de) | 1971-11-30 | 1973-06-14 | Bayer Ag | Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
DE2159361A1 (de) | 1971-11-30 | 1973-06-14 | Bayer Ag | Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
DE2159363A1 (de) | 1971-11-30 | 1973-06-14 | Bayer Ag | Antimikrobielle mittel |
DE2159360A1 (de) | 1971-11-30 | 1973-06-14 | Bayer Ag | Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
GB1384599A (en) | 1972-05-04 | 1975-02-19 | Colgate Palmolive Co | Coloured detergent compositions |
US3880871A (en) | 1973-09-27 | 1975-04-29 | Squibb & Sons Inc | Isothiocyanophenyl substituted imidazoles |
US4002643A (en) | 1975-06-27 | 1977-01-11 | Mcneil Laboratories, Inc. | Preparation of β-acyl pyrroles |
US4002749A (en) | 1975-08-12 | 1977-01-11 | E. R. Squibb & Sons, Inc. | Substituted indolinones |
US4053613A (en) | 1975-09-17 | 1977-10-11 | E. R. Squibb & Sons, Inc. | 1,3,thiazolinyl and 1,3 thiazinyl substituted indolinones |
DE2855306A1 (de) | 1978-12-21 | 1980-07-10 | Boehringer Sohn Ingelheim | Mittel zur senkung der herzfrequenz |
GR73560B (US06573293-20030603-C00084.png) | 1979-02-24 | 1984-03-15 | Pfizer | |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4343923A (en) | 1980-08-07 | 1982-08-10 | Armstrong World Industries, Inc. | Process for reducing the acid dye uptake of polyamide textile materials with N-acylimidazole compound |
CH646956A5 (de) | 1981-12-15 | 1984-12-28 | Ciba Geigy Ag | Imidazolide. |
EP0095285A1 (en) | 1982-05-21 | 1983-11-30 | Sumitomo Chemical Company, Limited | N-acylimidazoles, their production and use |
US4493642A (en) | 1982-12-27 | 1985-01-15 | Bogdon Glendon J | Orthodontic device and associated orthodontic method |
DE3310891A1 (de) | 1983-03-25 | 1984-09-27 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
US4489089A (en) | 1983-04-06 | 1984-12-18 | American Cyanamid Company | Substituted N-[ω-(1H-imidazol-1-yl)alkyl]-amides |
DE3480392D1 (en) | 1983-04-29 | 1989-12-14 | Ciba Geigy Ag | Imidazolides and their use as curing agents for polyepoxides |
DE3415138A1 (de) | 1984-04-21 | 1985-10-31 | Basf Ag, 6700 Ludwigshafen | N-(azolylcarbamoyl)-hydroxylamine und diese enthaltende fungizide |
DE3426419A1 (de) | 1984-07-18 | 1986-01-23 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
US4560700A (en) | 1985-02-08 | 1985-12-24 | Merrell Dow Pharmaceuticals Inc. | Pyrrole-3-carboxylate cardiotonic agents |
JPH078851B2 (ja) | 1985-07-29 | 1995-02-01 | 鐘淵化学工業株式会社 | 3−フエニルチオメチルスチレン誘導体 |
US4966849A (en) | 1985-09-20 | 1990-10-30 | President And Fellows Of Harvard College | CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression |
WO1993012786A1 (en) | 1986-07-10 | 1993-07-08 | Howard Harry R Jr | Indolinone derivatives |
US4853404A (en) | 1986-10-13 | 1989-08-01 | Tanabe Seiyaku Co., Ltd. | Phenoxyacetic acid derivatives composition and use |
US5202341A (en) | 1987-03-11 | 1993-04-13 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Hydroxystyrene compounds having tyrosine kinase inhibiting activity |
US4971996A (en) | 1987-03-11 | 1990-11-20 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Hydroxystyrene compounds which are useful as tyrosine kinase inhibitors |
US5089516A (en) | 1987-03-11 | 1992-02-18 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | 1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity |
US5043348A (en) | 1987-04-24 | 1991-08-27 | Cassella Aktiengesellschaft | Pyrrolealdehydes, their preparation and their use |
US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
DE3808071A1 (de) | 1988-03-11 | 1989-09-21 | Basf Ag | Verfahren zur herstellung von acylierten imidazolen |
US4868304A (en) | 1988-05-27 | 1989-09-19 | Iowa State University Research Foundation, Inc. | Synthesis of nitrogen heterocycles |
JPH06104658B2 (ja) | 1988-06-23 | 1994-12-21 | 三菱化成株式会社 | ピロールカルボン酸誘導体 |
CA1339784C (en) | 1988-06-23 | 1998-03-31 | Shinya Inoue | Pyrrolecarboxylic acid derivatives |
DE3824658A1 (de) | 1988-07-15 | 1990-01-18 | Schering Ag | N-hetaryl-imidazolderivate |
GB8816944D0 (en) | 1988-07-15 | 1988-08-17 | Sobio Lab | Compounds |
US5084280A (en) | 1988-12-15 | 1992-01-28 | Chapman Chemical Company | Wood preservation composition and method |
DE3902439A1 (de) | 1989-01-27 | 1990-08-02 | Basf Ag | Pflanzenschuetzende mittel auf basis von 1-aryl- bzw. 1-hetarylimidazolcarbonsaeureestern |
US5047554A (en) | 1989-04-18 | 1991-09-10 | Pfizer Inc. | 3-substituted-2-oxindole derivatives |
CA2037923C (en) | 1989-07-25 | 1996-08-06 | Akihiro Kawaguchi | Oxindole derivative |
US5258357A (en) | 1989-10-07 | 1993-11-02 | Basf Aktiengesellschaft | Carboxamides, their preparation and their use as herbicides |
CA2032421A1 (en) | 1989-12-20 | 1991-06-21 | Mitsubishi Chemical Corporation | Pyrrolealdehyde derivative |
GB9004483D0 (en) | 1990-02-28 | 1990-04-25 | Erba Carlo Spa | New aryl-and heteroarylethenylene derivatives and process for their preparation |
CA2012634A1 (en) | 1990-03-20 | 1991-09-20 | Hassan Salari | Tyrphostins for treatment of allergic, inflammatory and cardiovascular diseases |
US5196446A (en) | 1990-04-16 | 1993-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Certain indole compounds which inhibit EGF receptor tyrosine kinase |
US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
IT1247509B (it) | 1991-04-19 | 1994-12-17 | Univ Cagliari | Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
ES2108120T3 (es) | 1991-05-10 | 1997-12-16 | Rhone Poulenc Rorer Int | Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf. |
GB9115160D0 (en) | 1991-07-12 | 1991-08-28 | Erba Carlo Spa | Methylen-oxindole derivatives and process for their preparation |
US5124347A (en) | 1991-07-31 | 1992-06-23 | Warner-Lambert Co. | 3-5-ditertiarybutylphenyl-4-hydroxymethylidene derivatives of 1,3-dihydro-2H-indole-2-ones as antiinflammatory agents |
AU664392B2 (en) | 1991-10-18 | 1995-11-16 | Monsanto Technology Llc | Fungicides for the control of take-all disease of plants |
US5389661A (en) | 1991-12-05 | 1995-02-14 | Warner-Lambert Company | Imidazole and 1,2,4-triazole derivatives with angiotensin II antagonist properties |
US5322950A (en) | 1991-12-05 | 1994-06-21 | Warner-Lambert Company | Imidazole with angiotensin II antagonist properties |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
FR2689397A1 (fr) | 1992-04-01 | 1993-10-08 | Adir | Utilisation des dérivés de la 3-(3,5-Ditert-Butyl-4-Hydroxybenzylidenyl) Indoline-2-one pour l'obtention de médicaments. |
DE4211531A1 (de) | 1992-04-06 | 1993-10-07 | Cassella Ag | Verfahren zur Herstellung von Pyrrolderivaten |
FR2694004B1 (fr) | 1992-07-21 | 1994-08-26 | Adir | Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent. |
US5565324A (en) | 1992-10-01 | 1996-10-15 | The Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
US5330992A (en) | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
JP3507124B2 (ja) | 1993-05-26 | 2004-03-15 | 塩野義製薬株式会社 | ベンジリデン誘導体の製造法 |
DE59402281D1 (de) | 1993-06-28 | 1997-05-07 | Bayer Ag | Massefärben von Kunststoffen |
US5332736A (en) | 1993-11-01 | 1994-07-26 | Ortho Pharmaceutical Corporation | Anti-convulsant aroyl aminoacylpyrroles |
US5610173A (en) | 1994-01-07 | 1997-03-11 | Sugen, Inc. | Formulations for lipophilic compounds |
GB9507298D0 (en) | 1995-04-07 | 1995-05-31 | Pharmacia Spa | Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5786488A (en) | 1996-11-13 | 1998-07-28 | Sugen, Inc. | Synthetic methods for the preparation of indolyquinones |
JP3246712B2 (ja) | 1995-11-15 | 2002-01-15 | 株式会社トクヤマ | エテニルアミド化合物の製造方法 |
EP0788890A1 (en) | 1996-02-06 | 1997-08-13 | Agfa-Gevaert N.V. | Dyes and dye-donor elements for thermal dye transfer recording |
CA2206201A1 (en) | 1996-05-29 | 1997-11-29 | Yoshiaki Isobe | Pyrazole derivatives and their pharmaceutical use |
KR100482268B1 (ko) | 1996-08-01 | 2005-04-14 | 메르클레 게엠베하 | 세포질 포스포리파제 a2의 저해제로서의 아실피롤디카르복실산 |
EP0984930B1 (en) * | 1997-05-07 | 2005-04-06 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
US6133305A (en) | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
EP1082305A4 (en) * | 1998-05-29 | 2001-09-26 | Sugen Inc | PYRROL SUBSTITUTED 2-INDOLINONE EFFECTIVE AS A PROTEIN KINASE INHIBITOR |
US6462072B1 (en) | 1998-09-21 | 2002-10-08 | Gpi Nil Holdings, Inc. | Cyclic ester or amide derivatives |
WO2000035434A2 (en) | 1998-12-14 | 2000-06-22 | Cellegy Pharmaceuticals, Inc. | Compositions and methods for the treatment of anorectal disorders |
CA2354873A1 (en) * | 1998-12-17 | 2000-06-22 | F. Hoffmann-La Roche Ag | 4-alkenyl (and alkynyl) oxindoles as inhibitors of cyclin-dependent kinases, in particular cdk2 |
US6284894B1 (en) | 1998-12-18 | 2001-09-04 | Nycomed Imaging As | Preparation of allylic aromatic compounds |
KR20010108063A (ko) * | 1998-12-31 | 2001-12-07 | 수젠, 인크. | 단백질 인산화 효소의 조절 및 암의 화학적 치료를 위한3-헤테로아릴리데닐-2-인돌리논 화합물 |
PT1233943E (pt) * | 1999-11-24 | 2011-09-01 | Sugen Inc | Formulações para agentes farmacêuticos ionizáveis como ácidos livres ou bases livres |
US20020010203A1 (en) * | 1999-12-22 | 2002-01-24 | Ken Lipson | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
PT1255752E (pt) * | 2000-02-15 | 2007-10-17 | Pharmacia & Upjohn Co Llc | Inibidores de proteína quinases: 2-indolinonas substituídas com pirrolo |
MY128450A (en) | 2000-05-24 | 2007-02-28 | Upjohn Co | 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
WO2002002551A1 (en) * | 2000-06-30 | 2002-01-10 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
EP1349852A2 (en) * | 2000-12-20 | 2003-10-08 | Sugen, Inc. | 4-(hetero)aryl substituted indolinones |
-
2001
- 2001-02-15 PT PT01914376T patent/PT1255752E/pt unknown
- 2001-02-15 WO PCT/US2001/004813 patent/WO2001060814A2/en active Application Filing
- 2001-02-15 ME MEP-2008-530A patent/ME00415B/me unknown
- 2001-02-15 RS YUP-614/02A patent/RS50444B/sr unknown
- 2001-02-15 BR BRPI0117360A patent/BRPI0117360B8/pt not_active IP Right Cessation
- 2001-02-15 NZ NZ520640A patent/NZ520640A/en not_active IP Right Cessation
- 2001-02-15 CZ CZ20023081A patent/CZ303705B6/cs unknown
- 2001-02-15 MX MXPA02008021A patent/MXPA02008021A/es active IP Right Grant
- 2001-02-15 AT AT01914376T patent/ATE369359T1/de active
- 2001-02-15 IL IL15112701A patent/IL151127A0/xx active Protection Beyond IP Right Term
- 2001-02-15 DK DK01914376T patent/DK1255752T3/da active
- 2001-02-15 EA EA200200862A patent/EA005996B1/ru not_active IP Right Cessation
- 2001-02-15 CN CNB018072690A patent/CN1329390C/zh not_active Expired - Lifetime
- 2001-02-15 MY MYPI20010696A patent/MY130363A/en unknown
- 2001-02-15 AR ARP010100703A patent/AR034118A1/es active IP Right Grant
- 2001-02-15 BR BRPI0108394 patent/BRPI0108394B8/pt not_active IP Right Cessation
- 2001-02-15 DE DE122008000002C patent/DE122008000002I1/de active Pending
- 2001-02-15 US US09/783,264 patent/US6573293B2/en not_active Expired - Lifetime
- 2001-02-15 JP JP2001560198A patent/JP3663382B2/ja not_active Expired - Lifetime
- 2001-02-15 EP EP01914376A patent/EP1255752B1/en not_active Expired - Lifetime
- 2001-02-15 KR KR1020027010706A patent/KR100713960B1/ko active IP Right Grant
- 2001-02-15 AU AU2001239770A patent/AU2001239770B2/en not_active Expired
- 2001-02-15 SK SK1326-2002A patent/SK287142B6/sk not_active IP Right Cessation
- 2001-02-15 DE DE60129794T patent/DE60129794T2/de not_active Expired - Lifetime
- 2001-02-15 PL PL361209A patent/PL211834B1/pl unknown
- 2001-02-15 UA UA2002097427A patent/UA73976C2/uk unknown
- 2001-02-15 HU HU0204433A patent/HU228979B1/hu active Protection Beyond IP Right Term
- 2001-02-15 ES ES01914376T patent/ES2290117T3/es not_active Expired - Lifetime
- 2001-02-15 DE DE122010000004C patent/DE122010000004I1/de active Pending
- 2001-02-15 SI SI200130778T patent/SI1255752T1/sl unknown
- 2001-02-15 AU AU3977001A patent/AU3977001A/xx active Pending
- 2001-02-15 CA CA002399358A patent/CA2399358C/en not_active Expired - Lifetime
- 2001-02-15 PE PE2001000172A patent/PE20011083A1/es active IP Right Grant
- 2001-02-15 CO CO01012068A patent/CO5280092A1/es not_active Application Discontinuation
- 2001-07-04 TW TW090103496A patent/TWI306860B/zh not_active IP Right Cessation
-
2002
- 2002-08-13 NO NO20023831A patent/NO325532B1/no not_active IP Right Cessation
- 2002-08-13 IS IS6501A patent/IS2491B/is unknown
- 2002-09-10 BG BG107078A patent/BG65764B1/bg unknown
- 2002-09-13 HR HR20020751A patent/HRP20020751B1/xx not_active IP Right Cessation
-
2003
- 2003-04-14 US US10/412,690 patent/US20040063773A1/en not_active Abandoned
- 2003-05-12 HK HK03103304A patent/HK1051188A1/xx not_active IP Right Cessation
-
2005
- 2005-01-04 US US11/028,477 patent/US7125905B2/en not_active Expired - Lifetime
-
2006
- 2006-09-06 US US11/517,529 patent/US7572924B2/en not_active Expired - Lifetime
-
2007
- 2007-09-13 CY CY20071101186T patent/CY1108032T1/el unknown
-
2008
- 2008-01-08 NL NL300332C patent/NL300332I2/nl unknown
- 2008-01-09 LU LU91407C patent/LU91407I2/fr unknown
- 2008-01-15 FR FR08C0002C patent/FR08C0002I2/fr active Active
- 2008-02-04 LT LTPA2008002C patent/LTC1255752I2/lt unknown
- 2008-02-08 CY CY200800004C patent/CY2008004I2/el unknown
- 2008-12-08 NO NO2008019C patent/NO2008019I2/no unknown
-
2009
- 2009-12-29 NL NL300430C patent/NL300430I2/nl unknown
-
2010
- 2010-02-09 NO NO2010002C patent/NO2010002I2/no unknown
- 2010-02-11 BE BE2010C009C patent/BE2010C009I2/fr unknown
- 2010-03-03 LU LU91657C patent/LU91657I2/fr unknown
- 2010-03-09 CY CY2010004C patent/CY2010004I2/el unknown
-
2012
- 2012-01-09 CR CR20120009A patent/CR20120009A/es unknown
- 2012-01-09 CR CR20120007A patent/CR20120007A/es unknown
-
2019
- 2019-02-05 NO NO2019005C patent/NO2019005I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0108394B8 (pt) | inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos | |
BR0207494A (pt) | Derivados de 3-(4-amidopirrol-2-ilmetilideno)-2-indolinona como inibidores de proteìna quinase | |
TR200201505T2 (tr) | Terapötik maddeler olarak pirazolopirimidinler | |
BR0316350A (pt) | Diaminotriazóis úteis como inibidores de proteìna cinases | |
BR9910792A (pt) | Inibidores de quinase protéica 2-indolinona substituìda com pirrol | |
BRPI0410563B8 (pt) | compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas | |
BRPI0411868B8 (pt) | derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase | |
BRPI0413427A (pt) | derivados de piridilpirrol ativos como inibidores da cinase | |
EA200300248A1 (ru) | Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции | |
MXPA02005844A (es) | Inhibidores de cinasas de proteina. | |
BR0315912A (pt) | Compostos pirimìdicos com atividade antiproliferativa (ii) | |
YU49101A (sh) | Karboksiaril supstituisani difenil karbamidi kao inhibitori raf kinaze | |
BRPI0411863A (pt) | derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos | |
BR0312232A (pt) | Inibidores de caspases e seus usos | |
BRPI0510032A (pt) | tiofeno heteroaril aminas | |
GT200500020A (es) | Derivados de 1h-tieno[2,3-c]pirazol utiles como inhibidores de quinasa. | |
DK1268472T3 (da) | 3-aminopyrazolinhibitorer af cyclinafhængige kinaser | |
BR0213037A (pt) | Derivados de pirimidina | |
BR0009561A (pt) | 1,4-didro indeno [1,2-c] pirazóis substituìdos como inbidores de tirosina cinase | |
MXPA04005809A (es) | Inhibidores de proteinas quinasas. | |
BR0112655A (pt) | Derivados de pirrolidino como inibidores de metaloproteases | |
BR0113752A (pt) | Derivados piperidina para uso inibidores 2,3-óxido esqualeno lanoesterol ciclase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B09X | Republication of the decision to grant [chapter 9.1.3 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/12/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/02/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 15/02/2021 |
|
B22O | Other matters related to patents and certificates of addition of invention: legal action concerning patent |
Free format text: INPI NO 52402.012897/2021-28 ORIGEM: 14A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1087133-48.2021.4.01.3400 ACAO DE PROCEDIMENTO COMUM COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: PHARMACIA AND UPJOHN COMPANY E SUGEN, INC REU(S): INPI - INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL |
|
B19A | Notification of judicial decision: notification of judicial decision |
Free format text: PROCESSO INPI NO 52402.001366/2022-91 NUP: 00424.035864/2022-85 (REF. 1003240-43.2022.4.01.0000) INTERESSADOS: PHARMACIA AND UPJOHN COMPANY E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI. 2 SENTENCA: DEFIRO O PEDIDO DE ANTECIPACAO DA TUTELA RECURSAL FORMULADO NA INICIAL, PARA RESTABELECER A VIGENCIA DA PATENTE PI0108394-5, ATE A REALIZACAO DA PROVA PERICIAL, VISANDO A APURAR A DEMORA SUPOSTAMENTE INJUSTIFICADA DO INPI DURANTE O RESPECTIVO PROCESSO DE CONCESSAO. |
|
B16B | Notification of grant cancelled [chapter 16.2 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2629 DE 25/05/2021 CONFORME DETERMINADO NO PROCESSO INPI NO 52402.001366/2022-91 NUP: 00424.035864/2022-85 (REF. 1003240-43.2022.4.01.0000) QUANTO AO PRAZO DE VALIDADE. |
|
B21I | Extinguishment of a patent or of a certificate of addition of invention: publication cancelled |
Free format text: ANULADA A PUBLICACAO CODIGO 21.1 NA RPI NO 2630 DE 01/06/2021 CONFORME DETERMINADO NO PROCESSO INPI NO 52402.001366/2022-91 NUP: 00424.035864/2022-85 (REF. 1003240-43.2022.4.01.0000) |
|
B19A | Notification of judicial decision: notification of judicial decision |
Free format text: PROCESSO INPI NO 52402.003587/2022-01 AGRAVO DE INSTRUMENTO (202) 1011696-79.2022.4.01.0000 NUP: 00424.117998/2022-13 AGRAVANTE: HYPERMARCAS S/A, FAES FARMA S.A AGRAVADO: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL DECISAO: DEFIRO O PEDIDO DE ANTECIPACAO DA TUTELA RECURSAL FORMULADO NA INICIAL, PARA RESTABELECER A VIGENCIA DA PATENTE PI0108394-5 E SUSPENDER OS EFEITOS DO DESPACHO 16.3 DO INPI, ATE A REALIZACAO DA PROVA PERICIAL, VISANDO A APURACAO DA DEMORA SUPOSTAMENTE INJUSTIFICADA DO INPI DURANTE O RESPECTIVO PROCESSO DE CONCESSAO. |
|
B19A | Notification of judicial decision: notification of judicial decision |
Free format text: PROCESSO INPI NO 52402.004947/2022-84 NUP: 00407.013384/2022-71 (REF. 0118882-60.2022-1.00.0000) INTERESSADOS: EMS S/A DIVISAO HORTOLANDIA E OUTROS. SENTENCA: HOMOLOGADA A DESISTENCIA DOS AGRAVOS REGIMENTAIS DE HIPERA S/A E FAES FARMA S/A, TRANSITANDO EM JULGADO A DECISAO ANTERIOR QUE JULGOU PROCEDENTE A RECLAMACAO E RESTABELECEU OS EFEITOS DO DESPACHO 16.3 DO INPI. |
|
B16B | Notification of grant cancelled [chapter 16.2 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 16.2 NA RPI NO 2668 DE 22/02/2022 CONFORME DETERMINADO NO PROCESSO INPI NO 52402.004947/2022-84 NUP: 00407.013384/2022-71 (REF. 0118882-60.2022-1.00.0000) INTERESSADOS: EMS S/A DIVISAO HORTOLANDIA E OUTROS. SENTENCA: HOMOLOGADA A DESISTENCIA DOS AGRAVOS REGIMENTAIS DE HIPERA S/A E FAES FARMA S/A, TRANSITANDO EM JULGADO A DECISAO ANTERIOR QUE JULGOU PROCEDENTE A RECLAMACAO E RESTABELECEU OS EFEITOS DO DESPACHO 16.3 DO INPI. |
|
B21I | Extinguishment of a patent or of a certificate of addition of invention: publication cancelled |
Free format text: ANULADA A PUBLICACAO CODIGO 21.9 NA RPI NO 2668 DE 22/02/2022 CONFORME DETERMINADO NO PROCESSO INPI NO 52402.004947/2022-84 NUP: 00407.013384/2022-71 (REF. 0118882-60.2022-1.00.0000) INTERESSADOS: EMS S/A DIVISAO HORTOLANDIA E OUTROS. SENTENCA: HOMOLOGADA A DESISTENCIA DOS AGRAVOS REGIMENTAIS DE HIPERA S/A E FAES FARMA S/A, TRANSITANDO EM JULGADO A DECISAO ANTERIOR QUE JULGOU PROCEDENTE A RECLAMACAO E RESTABELECEU OS EFEITOS DO DESPACHO 16.3 DO INPI. |
|
B19A | Notification of judicial decision: notification of judicial decision |
Free format text: PROCESSO INPI NO 52402.001366/2022-91 NUP: 00848.001633/2023-78 (REF. 00424.035864/2022-85) INTERESSADOS: PHARMACIA AND UPJOHN COMPANY E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI. 2 SENTENCA:"...MANIFESTO-ME NO SENTIDO DE A LIMINAR/TUTELA PROVISORIA ANTERIORMENTE CONCEDIDA FOI CASSADA, NAO ESTANDO MAIS A ENTIDADE REPRESENTADA COMPELIDA A CUMPRIR, EM RAZAO DESTE PROCESSO, A OBRIGACAO ANTERIORMENTE DETERMINADA."DIANTE DO EXPOSTO, DEVE SER RESTABELECIDO O DESPACHO 16.3, QUE ALTEROU O PRAZO DO VIGENCIA DA PATENTE DE ACORDO COM A DECISAO DA ADI 5529. |